Histogen Income Statement 2022-2005 | HSTO

Brief overview of income trends at Histogen

The conclusions below are based on five years of reported results. Revenue reported by Histogen was 35.4 million dollars at the beginning of the period and 3.8 million dollars at the end. Overall revenue changed by −89.3%, equal to an annualized rate of about −36.1%. Sales followed a declining trajectory over the five years.

EBITDA changed from −$17.4 million to −$10.5 million (+39.8%). The operating result outpaced sales and points to improving efficiency. EBITDA margin moved from −49.3% to −278.7%. The margin contraction indicates weaker operating efficiency.

The final result was −17.4 million dollars initially and −10.6 million dollars in the final year. The negative result improved without reaching break-even.

Market value was 26.4 billion dollars at the start and 3.2 million dollars at the end. The market has not yet confirmed the improvement in fundamentals.

Summary assessment

The indicators point to a weaker financial profile. The financial profile benefits from improving net profitability. The weaker side of the profile includes weaker operating efficiency, a low EBITDA margin and weak sales momentum. The key question is whether sales can be converted into sustainable profit.